前列地尔对早期糖尿病肾病患者血清瘦素和脂联素的影响

The influence of alprostadil on the serum adiponectin and leptin in patients with early diabetic nephropathy

目的探讨前列地尔对早期糖尿病肾病患者血清瘦素和脂联素的影响。方法将98例早期糖尿病肾病患者随机分为两组，对照组48例，治疗组50例。对照组采用常规治疗，治疗组在常规治疗的基础上加用前列地尔，共治疗21d。分析治疗前后血清脂联素、瘦素、胰岛素抵抗水平。结果两组治疗后尿微量白蛋白排泄率显著下降，治疗组下降更明显（P〈0．05）；两组治疗后血清脂联素、瘦素、胰岛素抵抗均有明显改善，治疗组改善更明显（P〈0．05或P〈0．01）。结论前列地尔辅助治疗早期糖尿病’肾病可以明显降低胰岛素抵抗、瘦素和脂联素水平。

Objective To study the influence of alprostadil on the serum adiponectin and leptin in patients with early diabetic nephropathy. Methods 98 patients with early diabetic nephropathy were randomly divided into two groups, the control group（ n = 48 cases） and the treatment group（ n = 50 cases）. The patients of the control group were treated through the conventional treatment. However,the patients of the treatment group were treated plus alpros- tadil. They were treated for 21 days. The urinary albumin excretion rate （UAER）, adiponectin, leptin and insulin resistance were detected before and after treatment. Results The UAER , adiponectin leptin and insulin resistance were improved after treatment, while those of the treatment group were more significantly improved than those of the control group（P 〈 0.05 or P 〈 0.01 ）. Conclusion Alprostadil can improve the conditions of early diabetic nephropathy which is through improving the adiponectin and insulin resistance.